About kala pharmaceuticals inc. - KALA
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
KALA At a Glance
Kala Bio, Inc.
1167 Massachusetts Avenue
Arlington, Massachusetts 02476
| Phone | 1-781-996-5252 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -26,980,000.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
KALA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.213 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.072 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
KALA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -4,496,666.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
KALA Liquidity
| Current Ratio | 3.805 |
| Quick Ratio | 3.805 |
| Cash Ratio | 3.03 |
KALA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -83.05 |
| Return on Equity | -279.18 |
| Return on Total Capital | -385.649 |
| Return on Invested Capital | -132.048 |
KALA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |